PrognosDx Health Information

PrognosDx is a biotechnology company committed to eliminating the trial and error approach to cancer treatment through analysis of global histone modifications, powerful master switches of the genome and gatekeepers to aggressive tumor metabolism that reveal critical information about aggressiveness of disease or potential to respond to specific types of treatment. This revolutionary epigenetic technology in the short-term can help physicians personalize patient treatments by identifying molecular signatures specific to each patient’s tumor cells and in the long run revolutionizes drug development by targeting aggressive cancer cells. Based on four published international clinical studies, the company is currently aimed at clinical development of its PrognoScore™ laboratory test to help prostate cancer patients and their treating physicians select appropriate personalized treatments leading to improved patient outcomes while reducing overall healthcare costs. Originally developed at UCLA, PrognoScore™ addresses the shortcomings of routine tests such as pre-operative PSA or inconclusive Gleason scores by correctly identifying men with non-life threatening forms of prostate cancer who may benefit from avoiding unnecessary treatments including radiation and surgery.